Base de dados : LILACS
Pesquisa : C04.588.448 [Categoria DeCS]
Referências encontradas : 159 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 16 ir para página                         

  1 / 159 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1026602
Autor: Riva, Eloisa.
Título: Utilidad del seguimiento tomográfico de linfoma no Hodgkin en estadio temprano / Usefulness of tomographic tracking of non-Hodgkin lymphoma in early stage
Fonte: Salud(i)ciencia (Impresa) = Salud(i)ciencia (En linea);22(8):765-765, dic.-mar. 2018.
Idioma: es.
Descritores: Linfoma não Hodgkin
Tomografia Computadorizada por Raios X
Neoplasias Hematológicas
Limites: Seres Humanos
Responsável: AR392.1 - Biblioteca


  2 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1004256
Autor: Lorca, Luz Alejandra; Sacomori, Cinara; Balagué-Ávila, Valentina Paz; Pino-Márquez, Lorena Patricia; Quiroz-Vidal, Fabiola Andrea; Ortega, Leslie.
Título: Incidência e risco de quedas em pacientes tratados por neoplasias hematológicas na Unidade de Hematologia Intensiva / Incidence and risk of falls in patients treated for hematologic malignancies in the Intensive Hematology Unit / Incidencia y riesgo de caídas en pacientes tratados por neoplasias hematológicas en Unidad Hematología Intensiva
Fonte: Rev. latinoam. enferm. (Online);27:e3145, 2019. tab.
Idioma: pt.
Resumo: Objetivo: determinar a incidência e a taxa de risco de quedas em pacientes adultos tratados por neoplasias hematológicas na Unidade de Hematologia Intensiva de um hospital de referência. Método: corresponde a um estudo observacional retrospectivo. Foram avaliados 101 pacientes. A ocorrência de quedas foi obtida a partir do registro da unidade e as variáveis preditivas do modelo Hendrich II foram coletadas: sexo, presença de tontura ou vertigem, confusão mental, problemas de eliminação, depressão, uso de benzodiazepínicos, uso de anticonvulsivantes e o teste Get up and Go. Resultados: dois eventos de quedas foram relatados em 101 pacientes (incidência de 1,98% em um período de 1,5 ano). Usando o ponto de corte cinco do Modelo Hendrich II, identificou-se que 30 pacientes (29,7%) apresentaram risco de queda no primeiro dia de hospitalização, 41 (40,6%) ao meio e 38 (37,6%) no momento da alta hospitalar. Conclusões: pacientes tratados por neoplasias hematológicas apresentaram baixa incidência e alto risco de quedas durante a hospitalização.

Objective: to determine the incidence and rate of risk of falls in adult patients treated for hematologic malignancies in the Intensive Hematology Unit of a reference hospital. Method: this is a retrospective observational study. A total of 101 patients were evaluated. The occurrence of falls was obtained from records of the unit and the predictive variables of the Hendrich II model were collected, namely: sex, presence of dizziness or vertigo, mental confusion, elimination problems, depression, use of benzodiazepines, use of anticonvulsants, and the Get up and Go test. Results: two fall events were reported in 101 patients (incidence of 1.98% over a 1.5-year period). Based on the cut-off point 5 of the Hendrich II Model, 30 patients (29.7%) were at risk of fall at the moment of hospital admission, 41 (40.6%) in the middle of the hospitalization period, and 38 (37.6%) at the moment of hospital discharge. Conclusions: patients treated for hematological malignancies presented low incidence and high risk of falls during hospitalization.

Objetivo: determinar la incidencia y la tasa de riesgo de caídas en pacientes adultos tratados por neoplasias hematológicas en la Unidad de Hematología Intensiva de un hospital de referencia. Método: corresponde a un estudio observacional retrospectivo. Se evaluaron 101 pacientes. La ocurrencia de caídas se obtuvo del registro de la unidad y las variables predictivas del modelo Hendrich II fueron recopiladas: sexo, presencia de mareos o vértigo, confusión mental, problemas de eliminación, depresión, uso de benzodiacepina, uso de anticonvulsionantes y la prueba Get up and Go. Resultados: dos eventos de caídas fueron reportados en 101 pacientes (incidencia de 1,98% en un período de 1,5 años). Utilizando el punto de corte 5 del Modelo Hendrich II, fue identificado que 30 pacientes (29,7%) tenían riesgo de caída al ingreso hospitalario, 41 (40,6%) en la mitad y 38 (37,6%) al egreso hospitalario. Conclusiones: los pacientes tratados por neoplasias hematológicas presentaron una incidencia baja y un alto riesgo de caídas durante la hospitalización.
Descritores: Acidentes por Quedas/estatística & dados numéricos
Neoplasias Hematológicas/terapia
Hospitalização/estatística & dados numéricos
Unidades de Terapia Intensiva/estatística & dados numéricos
-Chile/epidemiologia
Hematologia
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  3 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-582744
Autor: Clark, Otávio; Faleiros, Enéas José de Matos.
Título: Cost of the treatment of myelodisplastic syndrome in Brazil
Fonte: Rev. bras. hematol. hemoter;33(1):31-34, Feb. 2011. ilus, tab.
Idioma: en.
Resumo: INTRODUCTION: Myelodysplastic syndrome is an incurable and rare hematological disease that affects the production of blood cells. One aim of treatment is to maintain the blood-cell count to near-normal levels. This is mainly achieved with hematopoietic- growth factors and transfusions. Our objective was to determine the cost of supportive treatment/care for patients with low and intermediate I risk myelodysplastic syndrome in respect to private healthcare plans in Brazil. METHOD: We adapted the National Comprehensive Cancer Network treatment guidelines for intermediate risk myelodysplastic syndrome patients to the Brazilian reality, adopting a decision tree to explore treatment combinations. Then, we calculated the costs for each branch of the tree, according to national prices. We also estimated total costs for a cohort of 100 patients, distributed across treatment combinations according to the expected epidemiology. We assumed a horizon of one year of treatment. RESULTS: The mean cost of treatment for low and intermediate I risk myelodysplastic syndrome is US$ 42,758/patient/year. This cost can vary from US$ 24,282 to US$ 121,952, according to patient characteristics and the treatment used. Overall, patients that require immunotherapy with antithymocyte globulins are associated with the highest cost. Those that achieve disease stability solely with the use of erythropoietin were associated with the lowest cost. CONCLUSION: In Brazil, treatment of low and intermediate I risk myelodysplastic syndrome is associated with a mean cost of the order of US$ 42,700/patient/year. New types of therapy have the potential to change this scenario if they can diminish the requirements for supportive care.
Descritores: Efeitos Psicossociais da Doença
Neoplasias Hematológicas
Neoplasias
Limites: Seres Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  4 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-601008
Autor: Barcelos, Michelle Maccarini; Santos-Silva, Maria Cláudia.
Título: Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
Fonte: Rev. bras. hematol. hemoter;33(4):290-296, 2011. ilus, tab.
Idioma: en.
Resumo: Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, mast cell disease, and unclassifiable myeloproliferative neoplasms. In the revised 2008 WHO diagnostic criteria for myeloproliferative neoplasms, mutation screening for JAK2V617F is considered a major criterion for polycythemia vera diagnosis and also for essential thrombocythemia and primary myelofibrosis, the presence of this mutation represents a clonal marker. There are currently two hypotheses explaining the role of the JAK2V617F mutation in chronic myeloproliferative neoplasms. According to these theories, the mutation plays either a primary or secondary role in disease development. The discovery of the JAK2V617F mutation has been essential in understanding the genetic basis of chronic myeloproliferative neoplasms, providing some idea on how a single mutation can result in three different chronic myeloproliferative neoplasm phenotypes. But there are still some issues to be clarified. Thus, studies are still needed to determine specific molecular markers for each subtype of chronic myeloproliferative neoplasm.
Descritores: Neoplasias Hematológicas
Leucemia Mieloide Crônica Atípica BCR-ABL Negativa
Doenças Mieloproliferativas-Mielodisplásicas
Mutação
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  5 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-601005
Autor: Garcia, Fernanda Bernadelli; Reis, Rafaella Kizzy Inácio dos; Silva, Lucas Emanuel Pinheiro da; Moraes-Souza, Helio.
Título: Analysis of the -398C/T polymorphism in the perforin gene in oncohematological patients
Fonte: Rev. bras. hematol. hemoter;33(4):274-276, 2011. ilus, tab.
Idioma: en.
Resumo: BACKGROUND: Recently, single nucleotide polymorphisms (SNPs) were identified in the promoter region of the perforin gene (PRF1) and it was found that the -398T mutant allele is correlated with lower amounts of protein in circulating CD8+ cytotoxic T lymphocytes. OBJECTIVE: The aim of this study was to investigate the presence of the -398C/T polymorphism in the perforin gene in oncohematological patients. Methods: Sixty-two patients with hematological malignancies treated at the teaching hospital of the Universidade Federal do Triângulo Mineiro were invited to participate in this study. The identification of the polymorphism was achieved by amplification using polymerase chain reaction, digestion using the TaqI enzyme and electrophoresis in 1 percent agarose gel. RESULTS: The heterozygous -398C/T polymorphism was identified in 16.7 percent patients with acute lymphoblastic leukemia, 40 percent with multiple myeloma, 50 percent with essential thrombocythemia, 14.3 percent with Hodgkin's disease, 7.7 percent with non-Hodgkin lymphoma and 33.3 percent with chronic lymphocytic leukemia. The homozygous mutant allele was identified in one mulatto individual (25 percent) with myelodysplastic syndrome. When Afro-Brazilian and Whites were analyzed together, there was a higher frequency of the -398T allele in patients than in healthy individuals (p-value = 0.0291). CONCLUSION:One patient was homozygous for the -398T allele. Based on these findings, further studies should be conducted to assess whether the presence of this polymorphism may be a risk factor for the development of hematologic malignancies.
Descritores: Polimorfismo Genético
Neoplasias Hematológicas
Polimorfismo de Nucleotídeo Único
Perforina
-Grupo com Ancestrais do Continente Africano
Grupo com Ancestrais do Continente Europeu
Limites: Seres Humanos
Masculino
Feminino
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  6 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Covas, Dimas Tadeu
Texto completo
Texto completo
Id: lil-600999
Autor: Covas, Dimas Tadeu.
Título: Perforin and hematological cancer
Fonte: Rev. bras. hematol. hemoter;33(4):254-255, 2011.
Idioma: en.
Descritores: Neoplasias Hematológicas
Perforina
Limites: Seres Humanos
Tipo de Publ: Comentário
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  7 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-978610
Autor: Marques, Angela da Costa Barcellos; Szczepanik, Ana Paula; Machado, Celina Angélica Mattos; Santos, Pâmella Naiana Dias; Guimarães, Paulo Ricardo Bittencourt; Kalinke, Luciana Puchalski.
Título: Hematopoietic stem cell transplantation and quality of life during the first year of treatment / Transplante de células-tronco hematopoiéticas e qualidade de vida durante o primeiro ano de tratamento / Trasplante de Células Tronco Hematopoyéticas y calidad de vida durante el primer año de tratamiento
Fonte: Rev. latinoam. enferm. (Online);26:e3065, 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: to evaluate the quality of life of adult patients with hematological cancer comparing Hematopoietic Stem Cell Transplantation modalities during the first year of treatment. Method: this is an observational and longitudinal research with 55 participants. Data collection was performed in six steps: before transplantation, pancytopenia, before hospital discharge, after 100, 180 and 360 days, in a reference hospital in Brazil for this treatment. The international instruments Quality of Life Questionnaire - Core 30 and Functional Assessment Cancer Therapy - Bone Marrow Transplantation were validated and translated into Portuguese (Brazil). Results: the mean age of participants was 36 years, 65% (n = 36) had leukemia diagnosis and 71% (n = 39) had undergone allogenic transplantation. In the Quality of Life Questionnarie - Core30 instrument, the pain symptom was significant between the first and second stages, and loss of appetite between the third and fourth stages, both in the allogenic group. In the Functional Assessment Cancer Therapy - Bone Marrow Transplantation, the functional well-being domain was significant between the third and fourth stages, also in the allogenic group. Conclusions: although the aggressiveness of treatment affects quality of life, patients consider it satisfactory after the first year. There are few significant differences between autologous and allogenic patients, and both groups have recovered in the course of the process.

RESUMO Objetivo: avaliar a qualidade de vida dos pacientes adultos com câncer hematológico comparando as modalidades de Transplante de Células-Tronco Hematopoiéticas durante o primeiro ano de tratamento. Método: pesquisa observacional, longitudinal, com 55 participantes; coleta de dados em seis etapas: pré-transplante, pancitopenia, pré-alta hospitalar, pós 100, 180 e 360 dias, em um hospital referência no Brasil para esse tratamento. Foram utilizados os instrumentos internacionais Quality of Life Questionnarie-Core 30 e Functional Assessment Cancer Therapy- Bone Marrow Transplantation, validados e traduzidos para a língua portuguesa (Brasil). Resultados: média de idade 36 anos, 65% (n=36) apresentaram diagnóstico de leucemia e 71% (n=39) submeteram-se ao transplante alogênico. No instrumento Quality of Life Questionnarie - Core30, o sintoma dor foi significante entre a primeira e a segunda etapa, e perda de apetite entre a terceira e a quarta etapa, ambos no grupo alogênico. No instrumento Functional Assessment Cancer Therapy- Bone Marrow Transplantation, o domínio bem-estar funcional apresentou-se significante entre a terceira e a quarta etapa, também no grupo alogênico. Conclusões: embora a agressividade do tratamento afete a qualidade de vida, os pacientes a consideram satisfatória após o primeiro ano. Há poucas diferenças significantes entre autólogos e alogênicos, e ambos se recuperam no decorrer do processo.

RESUMEN Objetivo: evaluar la calidad de vida de los pacientes adultos con cáncer hematológico comparando las modalidades de Trasplante de Células Tronco Hematopoyéticas durante el primer año de tratamiento. Método: investigación observacional, longitudinal, con 55 participantes; recogida de datos en seis etapas: pre trasplante, pancitopenia, pre alta hospitalaria, después de 100, 180 y 360 días, en un hospital referencia en Brasil para este tratamiento. Fueron utilizados los instrumentos internacionales Quality of Life Questionnarie-Core 30 y Functional Assessment Cancer Therapy- Bone Marrow Transplantation, validados y traducidos para la lengua portuguesa (Brasil). Resultados: media de edad 36 años, 65% (n=36) presentaron diagnóstico de leucemia y 71% (n=39) se sometieron al trasplante alogénico. En el instrumento Quality of Life Questionnarie - Core30, el síntoma dolor fue significativo entre la primera y la segunda etapa, y la pérdida de apetito entre la tercera y la cuarta etapa, ambos en el grupo alogénico. En el instrumento Functional Assessment Cancer Therapy- Bone Marrow Transplantation el dominio bienestar funcional se presentó significativo entre la tercera y la cuarta etapa, también en el grupo alogénico. Conclusiones: a pesar de que la agresividad del tratamiento afecta la calidad de vida, los pacientes la consideraron satisfactoria después del primer año. Existen pocas diferencias significativas entre autólogos y alogénicos, y ambos se recuperan en el transcurso del proceso.
Descritores: Enfermagem Oncológica/organização & administração
Transplante de Medula Óssea/psicologia
Transplante de Células-Tronco Hematopoéticas/psicologia
Neoplasias Hematológicas/cirurgia
-Qualidade de Vida
Brasil
Inquéritos e Questionários
Estudos Longitudinais
Limites: Seres Humanos
Masculino
Feminino
Adolescente
Adulto
Responsável: BR1.1 - BIREME


  8 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rego, Eduardo Magalhäes
Texto completo
Texto completo
Id: lil-670446
Autor: Rego, Eduardo Magalhães.
Título: The results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countries
Fonte: Rev. bras. hematol. hemoter;35(1):1-2, 2013. ilus.
Idioma: en.
Descritores: Leucemia Promielocítica Aguda
Resultado do Tratamento
Neoplasias Hematológicas
Países em Desenvolvimento
Rede Social
Limites: Seres Humanos
Tipo de Publ: Editorial
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  9 / 159 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-978403
Autor: Martinez Sánchez, Lina Maria; Jaramillo Jaramillo, Laura Isabel; Álvarez Hernández, Luis Felipe; Hernández Restrepo, Felipe; Ruiz Mejía, Camilo; Villegas Álzate, Juan Diego.
Título: Enfermedad Mínima Residual en leucemia: rompiendo el paradigma de remisión completa / Residual minimal disease: breaking the paradigm of complete remission
Fonte: Rev. cuba. hematol. inmunol. hemoter;34(1):21-32, ene.-mar. 2018. tab.
Idioma: es.
Resumo: Las malignidades hematológicas constituyen un grupo heterogéneo de condiciones. La enfermedad mínima residual (EMR) hace referencia a la presencia de enfermedad maligna hematológica, en pacientes que se encuentran en remisión según análisis convencionales. La EMR ha mostrado tener importancia pronóstica en condiciones como: leucemia mieloide aguda, leucemia mieloide crónica, mieloma múltiple, y en leucemia linfoide aguda y crónica. La detección ultrasensible de este estado podría permitir una mejor estratificación del riesgo y de igual forma abrir oportunidades para intervenciones terapéuticas tempranas. En el siguiente artículo se realiza una breve revisión acerca de la importancia pronóstica de la EMR en diferentes malignidades hematológicas(AU)

Hematological malignancies constitute a heterogeneous group of conditions. Residual minimal disease (RMS) refers to the presence of haematological malignancy in patients who are in remission if conventional pathological analyzes are used. RMS has been shown to have prognostic significance in conditions such as: acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, and acute and chronic lymphoblastic leukemia. Ultrasensitive detection of this condition could allow a better risk stratification and open opportunities for early therapeutic interventions. In the following article there will be a brief review about the prognostic importance of RMS in different hematologic malignancies(AU)
Descritores: Neoplasia Residual/diagnóstico
Neoplasias Hematológicas/prevenção & controle
Citometria de Fluxo/métodos
-Prognóstico
Limites: Seres Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CU1.1 - Biblioteca Médica Nacional


  10 / 159 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1006782
Autor: Mendonza, Diego; Gómez, Patricio; Cuesta, Paola.
Título: Leucemia mieloide aguda en adulto mayor comórbido. A propósito de un caso / Acute myeloid leukemia in a comorbid adult. About a case
Fonte: Rev. Eugenio Espejo;13(1):53-61, Ene-Jul. 2019.
Idioma: es.
Resumo: Caso clínico: paciente masculino de 81 años de edad, con cuadro de 24 horas de evolución secundario a caída, caracterizado por somnolencia, desorientación en persona, tiempo y espacio, incontinencia urinaria y dificultad para la deambulación, motivo por el cual se le efectúa una tomografía simple de cráneo encontrándose hematomas subdurales bilaterales, presenta episodios de sangrado recurrente y leucocitosis sostenida , en frotis de sangre periférica se observó 28% de blastos por lo que se realiza una biopsia de medula ósea descubriéndose un cariotipo medular compatible con leucemia mieloide aguda, debido a sus características clínicas y a su mala evolución fue catalogado como paciente paliativo. Conclusiones: la leucemia mieloide aguda es una patología hematológica cuya evolución al no ser detectada genera un alto grado de mortalidad, sobre todo en el adulto mayor comórbido.

It was presented a clinical case of a male patient of 81 years of age, with a 24-hour of secondary evolution to a fall. It was characterized by drowsiness, disorientation in person, time and space, urinary incontinence and difficulty in walking, that was why a simple skull tomography was performed, in which bilateral subdural hematomas were found. The patient presented episodes of recurrent bleeding and sustained leukocytosis. Peripheral blood smear showed 28% of blasts, so a bone marrow biopsy was performed, revealing a medullary karyotype compatible with acute myeloid leukemia. The patient was classified as palliative due to its clinical characteristics and evolution. The hematological pathology above was potentially fatal. If this one was not detected early, it would generate an accelerated unfavorable evolution, especially in the elderly comorbid, as occurred in the case presented.
Descritores: Neoplasias Hematológicas
Doenças Hematológicas
Doenças Sanguíneas e Linfáticas
-Síndromes Paraneoplásicas
Neoplasias
Processos Neoplásicos
Limites: Seres Humanos
Masculino
Idoso de 80 Anos ou mais
Tipo de Publ: Relatos de Casos
Responsável: EC107 - Dirección Nacional de Inteligencia de la Salud



página 1 de 16 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde